Research in Social and Administrative Pharmacy
Volume 1, Issue 2 , Pages 185-210 , June 2005

Television advertisement format and the provision of risk information about prescription drug products☆

  • Lewis H. Glinert, Ph.D.

      Affiliations

    • Dartmouth College, Program in Linguistics and Cognitive Science, 6191 Bartlett Hall, Hanover, NH 03755, USA
    • ,
  • Jon C. Schommer, Ph.D.

      Affiliations

    • University of Minnesota, Department of Pharmaceutical Care and Health Systems, 308 Harvard Street SE, Minneapolis, MN 55455, USA
    • Corresponding Author InformationCorresponding author.

References 

  1. Kaphingst KA, DeJong W. The educational potential of direct-to-consumer prescription drug advertising. Health Aff. 2004;23:143–150
  2. FDA . Direct-to-consumer advertising of prescription drugs: patient survey. Accessed August 15, 2004 at http://www.fda.gov/cder/ddmac/Presentations/KitHMCC2002out/index.htm2002;
  3. Hoen ET. Direct-to-consumer advertising: for better profits or for better health?. Am J Health Syst Pharm. 1998;55:594–597
  4. Eagle L, Chamberlain K. Prescription medication advertising: professional discomfort and potential patient benefits – can the two be balanced?. Int J Advert. 2004;23:69–90
  5. Auton F. The advertising of pharmaceuticals direct to consumers: a critical review of the literature and debate. Int J Advert. 2004;23:5–52
  6. Menon AM, Deshpande AD, Zinkhan GM, Perri M. A model assessing the effectiveness of direct-to-consumer advertising: integration of concepts and measures from marketing and healthcare. Int J Advert. 2004;23:91–118
  7. Main JK, Argo JJ, Huhmann BA. Pharmaceutical advertising in the USA: information or influence?. Int J Advert. 2004;23:119–142
  8. Desselle SP. Direct-to-consumer prescription drug advertising and pharmacy practice. Am J Pharm Educ. 2004;68:article 66
  9. Schommer JC, Doucette WR, Mehta BH. Rote learning after exposure to a direct-to-consumer television advertisement for a prescription drug. Clin Ther. 1998;20:617–632
  10. Glasgow C, Schommer JC, Gupta K, Pierson K. Promotion of prescription drugs to consumers: case study results. J Manag Care Pharm. 2002;8:512–518
  11. Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman M, Leitman R. Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Aff. 2003;W3:82–95
  12. Lyles A. Direct marketing of pharmaceuticals to consumers. Annu Rev Public Health. 2002;23:73–91
  13. Pines W. A history and perspective on direct-to-consumer promotions. Food Drug Law J. 1999;54:489–518
  14. Mello MM, Rosenthal M, Neuron PJ. Direct-to-consumer advertising and shared liability for pharmaceutical manufacturers. JAMA. 2003;287:477–481
  15. AMA . The Council on Ethical and Judicial Affairs of the American Medical Association. Direct-to-consumer advertisements of prescription drugs. Food Drug Law J. 2000;55:119–124
  16. FDA . Direct-to-consumer advertising of prescription drugs: Physician Survey. Accessed on August 15, 2004 at http://www.fda.gov/cder/ddmac/globalsummit2003.2002;
  17. Reissman D. New drugs and DTC advertising: friend or foe?. Drug Benefit Trends. 1998;10:16
  18. Waltermire RD. Viewpoint: direct-to-consumer advertising of Rx drugs can be harmful to your health. Drug Benefit Trends. 1998;10:60–61
  19. Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer prescription drug advertising and the public. J General Intern Med. 1999;14:651–657
  20. DDMAC untitled letter dated April 20 to Glaxo Wellcome concerning Zyban (bupropion HCl) sustained-release tablets. Accessed on October 17, 2004 at http://www.fda.gov/cder/warn/warn1998.htm. 1998.
  21. Scheineson M. Outline of FDA/FTC marketing rules, paper presented at the DIA (Drug Information Association) ‘Marketing of Pharmaceuticals’ meeting, February 24–25, 2003, New York.
  22. Morris LA, Pines WL. Regulation of pharmaceutical promotion in the twenty-first century. Drug Inf J. 2000;34:861–873
  23. Morris L. Prescription drug advertising to consumers: brief summary formats for television and magazine advertisements. Report supported by FDA contracts to Vanguard Corp, Westat Inc, Prism Corp and Biomedical Information Inc. 1983.
  24. Morris L, Ruffner M, Klimberg R. Warning disclosures for prescription drugs. J Advert Res. 1987;25:25–32
  25. Brinberg D, Morris LA. Advertising prescription drugs to consumers. Adv Mark Public Policy. 1987;1:1–40
  26. Morris LA, Mazis MB, Brinberg D. Risk disclosures in televised prescription drug advertising to consumers. J Public Policy Mark. 1989;8:64–80
  27. Kopp SW, Bang HK. Benefit and risk information in prescription drug advertising: review of empirical studies and marketing implications. Health Mark Q. 2000;17:39–56
  28. Christensen TP, Ascione FJ, Bagozzi RP. Understanding how elderly patients process drug information: a test of a theory of information processing. Pharm Res. 1997;14:1589–1596
  29. Tucker GK, Smith MC. Direct-to-consumer advertising: effects of different formats of warning information disclosure on cognitive reactions of adults. J Pharm Market Manage. 1987;2:27–41
  30. Davis JJ. Riskier than we think? The relationship between risk statement completeness and perceptions of direct to consumer advertised prescription drugs. J Health Commun. 2000;5:349–369
  31. Nikam PT. Impact of risk disclosures through direct-to-consumer advertising on elderly consumers' behavioral intent. Unpublished Dissertation, 2003. The Ohio State University, Columbus, OH.
  32. Whipple TW, McManamon MK. Implications of using male and female voices in commercials: An exploratory study. J Advert. 2002;31:79–91
  33. Puto CP, Wells WD. Informational and transformational advertising: the differential effects of time. In:  Kinnear Thomas C editors. Adv Consum Res. 11:1984;p. 638–643
  34. Duncan CP, Nelson JE. Effects of humor in a radio advertising experiment. J Advert. 1985;14:33–4064
  35. Labor SL, Schommer JC, Pathak DS. Information overload with written prescription drug information. Drug Inf J. 1995;29:1317–1328
  36. Lichtenstein DR, Bearden WO. Contextual influences on perceptions of merchant-supplied reference prices. J Consum Res. 1989;16:55–66
  37. Shimp TA, Bearden WO. Warranty and other extrinsic cue effects on consumers' risk perceptions. J Consum Res. 1982;9:38–46
  38. Bettman JR. Perceived risk and its components: a model and empirical test. J Mark Res. 1973;X:184–190
  39. Dowling GR. Perceived risk: the concept and its measurement. Psychol Mark. 1986;3:193–210
  40. Montgomery GH, Erblich J, DiLorenzo T, Bovbjerg DH. Family and friends with disease: their impact on perceived risk. Prev Med. 2003;37:242–249
  41. Cacioppo JT, Petty RE. The need for cognition. J Pers Soc Psychol. 1982;42:116–131
  42. Schommer JC, Sullivan DL, Haugtvedt CL. Patients' role orientation for pharmacist consultation. J Soc Adm Pharm. 1995;12:33–42
  43. Maheswara D, Sternthal B. The effects of knowledge, motivation, and type of message on ad processing and product judgments. J Consum Res. 1990;17:66–73
  44. Bloch PH. An exploration into the scaling of consumers' involvement with a product class. In:  Monroe KB editors. Adv Consum Res. 8:1981;p. 61–65
  45. Celsi RL, Olson JC. The role of involvement in attention and comprehension processes. J Consum Res. 1988;15:210–224
  46. Petty RE, Cacioppo JT, Schumann D. Central and peripheral routes to advertising effectiveness: the moderating role of involvement. J Consum Res. 1983;10:135–146
  47. Childers TL. Assessment of the psychometric properties of an opinion leadership scale. J Mark Res. 1986;23:184–188
  48. Kirk RE. Experimental Design, Procedures for the Behavioral Sciences. 2nd ed. Belmont, CA: Brooks/Cole Publishing Company, Division of Wadsworth, Inc; 1982;40-41, 144-145, 840-841

☆ Partial funding for this study was provided through an unrestricted grant from Pharmacia Corporation.

PII: S1551-7411(05)00036-7

doi: 10.1016/j.sapharm.2005.03.004

Research in Social and Administrative Pharmacy
Volume 1, Issue 2 , Pages 185-210 , June 2005

Article Tools

* Image Usage & Resolution